Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees

T van der Poll, M Levi, C E Hack, H ten Cate, S J van Deventer, A J Eerenberg, E R de Groot, J Jansen, H Gallati, H R Büller, T van der Poll, M Levi, C E Hack, H ten Cate, S J van Deventer, A J Eerenberg, E R de Groot, J Jansen, H Gallati, H R Büller

Abstract

The role of interleukin 6 (IL-6) in the toxic sequelae of sepsis is controversial. To assess the part of IL-6 in inflammatory responses to endotoxin, we investigated eight chimpanzees after either a bolus intravenous injection of Escherichia coli endotoxin (n = 4; 4 ng/kg) or after the same dose of endotoxin with a simultaneous bolus intravenous injection of an anti-IL-6 mAb (30 mg; n = 4). Anti-IL-6 did not affect the induction of the cytokine network (tumor necrosis factor [TNF], soluble TNF receptors types I and II, and IL-8) by endotoxin, nor did it influence the occurrence of a neutrophilic leukocytosis and neutrophil degranulation, as monitored by the measurement of elastase-alpha 1-antitrypsin complexes. In contrast, anti-IL-6 markedly attenuated endotoxin-induced activation of coagulation, monitored with the plasma levels of the prothrombin fragment F1+2 and thrombin-antithrombin III complexes, whereas activation of fibrinolysis, determined with the plasma concentrations of plasmin-alpha 2-antiplasmin complexes, remained unaltered. We conclude that IL-6 does not have a feedback effect on the release of other cytokines after injection of endotoxin, and that it is not involved in endotoxin-induced neutrophilia or neutrophil degranulation. IL-6 is, however, an important intermediate factor in activation of coagulation in low grade endotoxemia in chimpanzees.

References

    1. Eur J Immunol. 1988 Oct;18(10):1535-40
    1. Cytometry. 1985 Sep;6(5):401-6
    1. Blood. 1989 Jan;73(1):108-10
    1. Cell Immunol. 1989 Jul;121(2):280-9
    1. Blood. 1989 Oct;74(5):1704-10
    1. J Clin Invest. 1989 Oct;84(4):1045-9
    1. J Exp Med. 1989 Nov 1;170(5):1627-33
    1. J Immunol. 1989 Dec 1;143(11):3517-23
    1. Lab Invest. 1989 Dec;61(6):588-602
    1. Blood. 1990 Jan 1;75(1):40-7
    1. J Immunol. 1990 Jul 15;145(2):561-8
    1. Blood. 1990 Dec 15;76(12):2520-6
    1. J Immunol Methods. 1991 Apr 8;138(1):47-56
    1. FASEB J. 1991 Aug;5(11):2567-74
    1. Cytokine. 1991 Mar;3(2):149-54
    1. J Clin Invest. 1991 Oct;88(4):1155-60
    1. Prog Clin Biol Res. 1991;367:101-9
    1. Blood. 1992 Feb 1;79(3):693-8
    1. J Lab Clin Med. 1992 Feb;119(2):159-68
    1. J Immunol. 1992 Mar 15;148(6):1746-52
    1. Immunology. 1992 Apr;75(4):669-73
    1. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845-9
    1. Infect Immun. 1992 Jul;60(7):2835-42
    1. Eur J Immunol. 1992 Sep;22(9):2395-401
    1. Blood. 1991 Nov 15;78(10):2708-14
    1. Eur J Immunol. 1992 Oct;22(10):2625-30
    1. Eur J Immunol. 1992 Nov;22(11):2819-24
    1. J Clin Invest. 1993 Jun;91(6):2850-60
    1. Blood. 1993 Jul 15;82(2):513-20
    1. J Immunol. 1993 Aug 15;151(4):2318-25
    1. JAMA. 1993 Aug 25;270(8):975-9
    1. J Clin Invest. 1994 Jan;93(1):114-20
    1. Blood. 1994 Jan 15;83(2):446-51
    1. J Exp Med. 1989 Jan 1;169(1):333-8

Source: PubMed

3
Tilaa